Showing 2951-2960 of 3185 results for "".
- JUVÉDERM VOLUMA™ XC Receives Unanimous Recommendation from FDA Panelhttps://practicaldermatology.com/news/20130514-juvderm_voluma_xc_receives_unanimous_recommendation_from_fda/2459545/The US Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augme
- Free Skin Health Screenings This Weekendhttps://practicaldermatology.com/news/20130510-free_skin_health_screenings_this_weekend/2459549/In the interest of Skin Cancer Awareness Month, Sam's Clubs nationwide are offering free skin health screenings on Saturday, May 11 from 11am-3pm to members and non members. Those screened are being encouraged to take results to a dermatologist to get proper treatment and advice after their exams. T
- OXY Unveils Overhauled Acne Lineshttps://practicaldermatology.com/news/20130507-oxy_unveils_overhauled_acne_lines/2459550/After 30 years, the OXY brand (Mentholatum Company) has had a makeover and now offers two distinct lines grouped by active ingredients designed to either kill acne (benzoyl peroxide) or provide maintenance for acne-prone skin (salicylic acid). The OXY Maximum Action line includes, among others, OXY
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- Angela Bennett Appointed as La Roche-Posay VPhttps://practicaldermatology.com/news/20130418-angela_bennett_appointed_as_la_roche-posay_vp/2459561/L'Oréal USA named Angela Bennett the Vice President of La Roche-Posay. A graduate of Loyola University in Baltimore, MD where she earned a degree in Business Administration, Bennett brings a wealth of experience, having worked with many global brands and has established solid relationships wi
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Obagi Fate Uncertain as New Details Emergehttps://practicaldermatology.com/news/20130403-obagi_fate_uncertain_as_new_details_emerge/2459573/Following a bidding war with rival Merz Pharma Group, Valeant Pharmaceuticals appears set to acquire Obagi Medical Products. Valeant's original offer came in March, when the company announced that it would acquire Obagi at $19.75 per share, in a deal worth approximately $344 million. Then, in early
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al